Cara Therapeutics Gelecekteki Büyüme
Future kriter kontrolleri 2/6
Cara Therapeutics kazanç ve gelirinin sırasıyla yıllık 39.4% ve 49.7% oranında artması tahmin edilirken, EPS'nin yıllık 54.9% oranında büyümesi bekleniyor.
Anahtar bilgiler
39.4%
Kazanç büyüme oranı
54.9%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 23.7% |
| Gelir büyüme oranı | 49.7% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 07 Oct 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues
Nov 01
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jul 18We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope
May 29Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S
May 25We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Feb 16The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%
Dec 19News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts
Nov 04Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?
Oct 25Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?
Jul 20Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper
Jun 04News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat
Mar 11Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates
Feb 15We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth
Feb 06We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow
Oct 18Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
Sep 28Cara Therapeutics hires new finance chief
Sep 12Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Sep 01Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
Aug 19Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M
Aug 08Calls A Much Safer Way To Buy Cara Therapeutics
Jun 24We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Jun 15Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts
May 12Taking A (Speculative) Position In Cara Therapeutics
Mar 21Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth
Mar 09Cara Therapeutics: De-Risked And Extremely Attractive
Dec 25Checking Back In On Cara Therapeutics
Nov 01Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA
Aug 21The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically
Aug 15Cara Therapeutics: 200% Upside Possible With FDA Approval
Aug 11Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive
Jul 19Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 7 | -37 | N/A | -36 | 3 |
| 12/31/2025 | 6 | -46 | N/A | -52 | 3 |
| 12/31/2024 | 7 | -74 | N/A | -63 | 3 |
| 6/30/2024 | 11 | -111 | -83 | -80 | N/A |
| 3/31/2024 | 17 | -123 | -91 | -88 | N/A |
| 12/31/2023 | 21 | -119 | -94 | -92 | N/A |
| 9/30/2023 | 21 | -117 | -99 | -98 | N/A |
| 6/30/2023 | 27 | -112 | -104 | -104 | N/A |
| 3/31/2023 | 43 | -84 | -88 | -88 | N/A |
| 12/31/2022 | 42 | -85 | -79 | -79 | N/A |
| 9/30/2022 | 39 | -89 | -57 | -56 | N/A |
| 6/30/2022 | 49 | -66 | -45 | -45 | N/A |
| 3/31/2022 | 26 | -93 | -62 | -62 | N/A |
| 12/31/2021 | 23 | -88 | -60 | -60 | N/A |
| 9/30/2021 | 134 | 24 | 23 | 23 | N/A |
| 6/30/2021 | 123 | 8 | 15 | 16 | N/A |
| 3/31/2021 | 129 | 14 | 9 | 9 | N/A |
| 12/31/2020 | 135 | 8 | -6 | -5 | N/A |
| 9/30/2020 | 28 | -99 | -119 | -119 | N/A |
| 6/30/2020 | 24 | -115 | -123 | -123 | N/A |
| 3/31/2020 | 24 | -113 | -120 | -120 | N/A |
| 12/31/2019 | 20 | -106 | -109 | -109 | N/A |
| 9/30/2019 | 21 | -98 | -102 | -102 | N/A |
| 6/30/2019 | 20 | -85 | -97 | -97 | N/A |
| 3/31/2019 | 18 | -79 | -31 | -31 | N/A |
| 12/31/2018 | 13 | -74 | -22 | -22 | N/A |
| 9/30/2018 | 8 | -68 | -9 | -9 | N/A |
| 6/30/2018 | 3 | -61 | 1 | 1 | N/A |
| 3/31/2018 | N/A | -53 | N/A | -52 | N/A |
| 12/31/2017 | 1 | -58 | N/A | -55 | N/A |
| 9/30/2017 | 1 | -66 | N/A | -57 | N/A |
| 6/30/2017 | 1 | -65 | N/A | -60 | N/A |
| 3/31/2017 | 1 | -69 | N/A | -59 | N/A |
| 12/31/2016 | 0 | -57 | N/A | -47 | N/A |
| 9/30/2016 | 0 | -45 | N/A | -38 | N/A |
| 6/30/2016 | 3 | -38 | N/A | -33 | N/A |
| 3/31/2016 | 3 | -31 | N/A | -26 | N/A |
| 12/31/2015 | 4 | -25 | N/A | -21 | N/A |
| 9/30/2015 | 5 | -19 | N/A | -23 | N/A |
| 6/30/2015 | 3 | -21 | N/A | -20 | N/A |
| 3/31/2015 | 3 | -19 | N/A | -20 | N/A |
| 12/31/2014 | 3 | -18 | N/A | -18 | N/A |
| 9/30/2014 | 3 | -16 | N/A | -17 | N/A |
| 6/30/2014 | 3 | -14 | N/A | -16 | N/A |
| 3/31/2014 | 12 | -6 | N/A | 2 | N/A |
| 12/31/2013 | 12 | -3 | N/A | 3 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: CARA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Kazançlar ve Piyasa: CARA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Yüksek Büyüme Kazançları: CARA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Gelir ve Pazar: CARA şirketinin gelirinin (yıllık 49.7% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: CARA şirketinin gelirinin (yıllık 49.7% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: CARA 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok